Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like L*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000083	Laboratoire HRA Pharma	03/31/2020	76336008060	Lysodren (mitotane) 500 mg tablets 100 count bottles	01/13/2020	83.10	922.10	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Column 6: Patent(s) expired. Product FDA approved 1970. Column 21: WAC at Intro to Market unknown. Introducted to U.S. market in 1970. WAC at market introduction unknown. NDC change in March 2019. 5 year pricing history believed to be $479.95 until 3/2019.
Rx0000083	Laboratoire HRA Pharma	03/31/2020	76336045518	Metopirone (metryapone) 250 mg capsules 18 count bottles	01/13/2020	38.05	422.00	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	HRA Pharma acquired Metopirone from Novartis in 2011 and began US distribution in 2015 (exact date unknown). WAC at introduction to market unknown. 5 year price history included. Original approval 1961
Rx0000083	Laboratoire HRA Pharma	09/30/2020	76336045518	Metopirone 250 mg capsules 18 count bottles	07/14/2020	105.50	527.50	None	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Product was FDA approved 1961. Innovator company was Novartis. Product was acquired by HRA Pharma from Novartis in 2011. Acquisition price of the product is unknown.
Rx0000089	Lannett Company, Inc.	12/31/2020	00527169801	CODEINE SULFATE 30 MG TABLET	11/23/2020	79.50	119.25	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	12/31/2020	00527147501	DIETHYLPROPION 25 MG TABLET	11/23/2020	22.30	44.60	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	12/31/2020	00527147701	DIETHYLPROPION ER 75 MG TABLET	11/23/2020	42.18	126.54	None	Single Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	12/31/2020	54838051240	Doxepin Hydrochloride Oral Solution 10mg/mL - 120mL	11/23/2020	37.92	56.88	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields were not filled out because this drug was not acquired within the previous 5 years.
Rx0000089	Lannett Company, Inc.	03/31/2020	54838055170	Escitalopram Oxalate Oral Solution 5mg/5ml - 240ml	01/31/2020	8.00	160.00	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	06/02/2015	Silarx	None	1	Lannett Company Acquired Silarx Company in 2015	152.00	None	2013	152.00	None	None
Rx0000089	Lannett Company, Inc.	12/31/2020	62175010601	ISOSORBIDE MONONIT 10 MG TAB	11/23/2020	7.74	48.47	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	12/31/2020	62175010701	ISOSORBIDE MONONIT 20 MG TAB	11/23/2020	17.75	50.75	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	03/31/2020	00527194313	Memantine Oral Solution 2mg - 360ml	01/31/2020	292.35	817.00	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	03/31/2020	62175048537	Verapamil HCl 100 MG Capsule Extended Release 24 Hour 100 EA	01/31/2020	40.27	487.69	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	03/31/2020	62175048637	Verapamil HCl 200 MG Capsule Extended Release 24 Hour 100 EA	01/31/2020	51.86	628.10	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000089	Lannett Company, Inc.	03/31/2020	62175048737	Verapamil HCl 300 MG Capsule Extended Release 24 Hour 100 EA	01/31/2020	75.40	913.17	None	Non-innovator Multiple Source Drug	None	1	No change or improvement in the product which necessitated the price increase, however, increase was due to economic and market conditions.	None	None	1	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2020	11994001116	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS	01/01/2020	202.38	4250.05	03/16/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2020	11994001104	Definity® Vial for (Perflutren Lipid Microsphere) Injectable Solution, 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS	01/01/2020	50.60	1062.52	03/16/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	03/31/2020	11994001601	QUADRAMET® (Samarium Sm 153 Lexidronam Injection), 3 mL in 1 VIAL, SINGLE-DOSE (11994-016-01)	01/01/2020	1065.23	16282.88	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000243	Larken Laboratories, Inc.	03/31/2020	70569015001	Allzital 100ct (Butalbital-Acetaminophen Tabs 25-325 MG	02/14/2020	286.31	1431.54	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This drug was not acquired within the previous 5 years.
Rx0000276	LEO Pharma Inc.	03/31/2020	50419082806	DESONATE 0.05% GEL 60GM TB 60G	01/01/2020	35.72	630.97	08/03/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	564.22	513.39	2007	120.00	None	Market WAC effective 01/30/2007. Bayer NDC 50419082806 was replaced by Leo NDC 50222050460. Bayer NDC 50419082806 uses the same history as Leo NDC 50222050460.
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050460	DESONATE 0.05% GEL 60GM TUBE 60G	01/01/2020	35.72	630.97	08/03/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	564.22	513.39	2007	120.00	None	Market WAC effective 01/30/2007. LEO NDC 50222050460 replaces Bayer NDC 50419082806. LEO NDC 50222050460 uses the same history as Bayer NDC 50419082806.
Rx0000276	LEO Pharma Inc.	03/31/2020	50222030260	ENSTILAR AEROSOL FOAM, 1 CAN 60gm 0.005-0.064 %	01/01/2020	63.01	1113.28	12/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable
Rx0000276	LEO Pharma Inc.	03/31/2020	50222030266	ENSTILAR AEROSOL FOAM, 2 CANS 120 gm 0.005-0.064 %	01/01/2020	126.04	2226.56	12/10/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable
Rx0000276	LEO Pharma Inc.	03/31/2020	50222030350	FINACEA 15% FOAM 50GM CAN	01/01/2020	20.69	365.56	02/28/2029	Single Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2015	255.01	None	Market WAC effective 08/31/2015. We are reporting this NDC because it replaced the Bayer NDC 50419082901. The LEO NDC 50222030350 shares the same history as the Bayer NDC 50419082901. The market entry date for this LEO NDC 50222030350 was April 2020. WAC in Medispan for this LEO NDC reflects 1/1/2020 WAC for Bayer NDC 50419082901.
Rx0000276	LEO Pharma Inc.	03/31/2020	50419082901	FINACEA 15% FOAM 50GM CN	01/01/2020	20.69	365.56	02/28/2029	Single Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2015	255.01	None	Market WAC effective 08/31/2015. Bayer NDC 50419082901 was replaced by LEO NDC 50222030350. LEO NDC 50222030350 entered market in April 2020 and uses the same history as Bayer NDC 50419082901.
Rx0000276	LEO Pharma Inc.	03/31/2020	50419082502	FINACEA 15% GEL 50GM TB	01/01/2020	17.24	362.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2003	75.40	None	Market WAC effective 03/10/2005. No date listed for patent expiration information based on Orange book. We are reporting this NDC because the LEO NDC 50222050550 is a replacement for this NDC 50419082502. This Bayer NDC 50419082502 shares the same history as the LEO NDC 50222050550. No increase in price shown in Medispan for the Bayer NDC 50419082502.
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050550	FINACEA 15% GEL 50GM TUBE	01/01/2020	17.24	362.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	09/04/2018	Bayer Pharmaceuticals	None	1	None	326.89	297.44	2003	75.40	None	Market WAC effective 03/10/2005, No date listed for patent expiration information based on Orange book. LEO NDC 50222050550 replaces Bayer NDC 50419082502. LEO NDC 50222050550 uses the same history as Bayer NDC 50419082502.
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050247	PICATO (ingenaol mebutate 0.015%) Gel 3 x .47gm	01/07/2020	62.74	1108.37	05/15/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Patent Exp date different for .05%. Drug was not acquired and therefore the acquisition related fields are not applicable;
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050347	PICATO (ingenaol mebutate 0.05%) Gel 2 x .47gm	01/07/2020	62.74	1108.37	07/06/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Patent Exp date different for .015%. Drug was not acquired and therefore the acquisition related fields are not applicable;
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050166	TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 120g	01/01/2020	126.04	2226.56	01/27/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable
Rx0000276	LEO Pharma Inc.	03/31/2020	50222050106	TACLONEX TOPICAL SUSPENSION (0.005%, 0.064%) Solution 60g	01/01/2020	63.01	1113.28	01/27/2020	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired and therefore the acquisition related fields are not applicable
Rx0000196	Lexicon Pharmaceuticals	03/31/2020	70183012584	XERMELO Telotristat Ethyl 250 mg 84 tablets	01/02/2020	306.00	6559.00	02/27/2031	Single Source Drug	None	1	Lexicon’s focus on improving the lives of all patients we serve shapes our pricing decisions. Our pricing is designed to ensure full access by balancing affordability with availability of patient assistance programs for our patients in need while factoring in market dynamics of competitor pricing and changing reimbursement rates.	None	no change	None	None	None	None	None	None	None	None	None	None	None	Product developed internally. No acquistion.
Rx0000025	Lundbeck LLC	03/31/2020	67386082019	Northera 100mg. 90 Capsules	01/02/2020	204.95	2799.21	02/18/2021	Single Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386082119	Northera 200mg. 90 Capsules	01/02/2020	409.89	5598.40	02/18/2021	Single Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386082219	Northera 300mg. 90 Capsules	01/02/2020	614.84	8397.62	02/18/2021	Single Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386031401	Onfi 10mg. 100 Tablets	01/02/2020	191.12	2202.86	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386031501	Onfi 20mg. 100 Tablets	01/02/2020	382.23	4405.67	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386031321	Onfi Oral Suspension 2.5mg/mL 120mL Bottle	01/02/2020	100.41	1157.40	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386011101	Sabril 500mg. 100 Tablets	01/02/2020	1388.11	15999.84	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386021165	Sabril 500mg. 50 Packets 10mg. each	01/02/2020	694.06	7999.93	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386042101	Xenazine 12.5mg. 112 Tablets	01/02/2020	1339.43	15438.72	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.
Rx0000025	Lundbeck LLC	03/31/2020	67386042201	Xenazine 25.0mg. 112 Tablets	01/02/2020	2678.87	30877.45	None	Innovator Multiple Source Drug	None	1	Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies.	None	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields not completed as product was not acquired in the last 5 years.